Published in Urology on July 17, 2009
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | NCT00272038
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol (2012) 1.29
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12
Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (2011) 0.89
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer (2011) 0.82
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol (2015) 0.80
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocr Relat Cancer (2015) 0.77
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs (2012) 0.77
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med (2016) 0.75
HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res (2016) 0.75
Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol (2016) 0.75
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant (2009) 1.22
Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer (2009) 1.19
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys (2011) 1.01
Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol (2009) 0.98
90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol (2007) 0.89
Warfarin-induced limb gangrene in the setting of lung adenocarcinoma. Am J Hematol (2004) 0.88
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer (2010) 0.87
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant (2008) 0.79
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk (2011) 0.78
Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial. Breast J (2007) 0.76
Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question? J Clin Oncol (2005) 0.75
Erlotinib in lung cancer. N Engl J Med (2005) 0.75
Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care? J Clin Oncol (2006) 0.75
Disclosing the cancer diagnosis:the myth and the truth. J Clin Oncol (2010) 0.75
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy. Avicenna J Med (2011) 0.75
A KISS for "meaningful use" of EMR: keep it simple stupid. Mich Med (2012) 0.75
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up. Clin Colorectal Cancer (2007) 0.75